Theralase(R) Closes C$3.6 Million Brokered Financing
Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering")
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-24 5:01 PM EDT | Theralase Technologies Inc.
NorthPalm Commits Entire Cybeats Position to a 12-Month Lock-Up; 60 Million Shares Representing Approximately 30% of Cybeats
Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - NorthPalm Capital Corp. (CSE: NP) ("NorthPalm" or the "Company"), is pleased to announce that it has committed to a 12-month lock-up of its entire remaining position of 60,000,000 common shares of Cybeats Technologies Corp. (CSE: CYBT) ("Cybeats"), representing approximately 30% of Cybeats' outstanding shares. NorthPalm remains the largest institutional shareholder of Cybeats and is committed to maintaining a signif
Biotechnology, Healthcare and Hospitals, Health
2026-08-24 9:39 AM EDT | NorthPalm Capital Corp.
MustGrow Receives First Milestone Payment from Bayer AG
Saskatoon, Saskatchewan--(Newsfile Corp. - August 21, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) ("MustGrow") is pleased to
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-08-21 7:00 AM EDT | MustGrow Biologics Corp.
Noveris Health Sciences Announces Proposed Private Placement of Convertible Debentures for up to $500,000
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") is pleased to announce its intention to complete a non-brokered private placement of convertible debentures of the Company (the "Debentures") in an aggregate principal amount of up to $500,000, issuable in increments of $1,000 principal amount, for aggregate gross proceeds of up to $500,000 (the "Offering
2026-08-20 6:14 PM EDT | Noveris Health Sciences Inc.
iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
Woburn, Massachusetts--(Newsfile Corp. - August 20, 2026) - iSpecimen, (NASDAQ: ISPC) a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order. The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline. Through its network of healthcare and research partners, iSpecimen coo
2026-08-20 4:05 PM EDT | iSpecimen Inc.
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
Calgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is plea
Biotechnology, Pharmaceuticals, Health
2026-08-20 9:44 AM EDT | Hemostemix Inc.
Maxwell Biosciences' Spinout SHU.ai Announces Closing of $1M Financing Round
Austin, Texas--(Newsfile Corp. - August 20, 2026) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers®, December 5, 2025 incorporated its first spinout SHU.ai and June 27, 2026 announced the closing of SHU's $1 million Seed round. The round was oversubscribed and fully funded by private angel investors and led by Keiretsu Forum, "The World's Largest Angel Investor Network." The funds will support accelera
Biotechnology, Pharmaceuticals
2026-08-20 9:00 AM EDT | Maxwell Biosciences, Inc.
TempraMed Announces Extension of Maccabi Healthcare Services Agreement
Toronto, Ontario--(Newsfile Corp. - August 20, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator focused on temperature-sensitive medication protection, is pleased to announce that Maccabi Healthcare Services ("Maccabi"), Israel's second-largest health maintenance organization ("HMO"), has exercised its option to extend its agreement with TempraMed for an additional year u
Technology, Biotechnology, Pharmaceuticals, Health
2026-08-20 7:00 AM EDT | TempraMed Technologies Ltd.
Marvel Biosciences Expands Private Placement to Quebec
Calgary, Alberta--(Newsfile Corp. - August 19, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it is expanding its previously announced private placement (see July 16, 2026 press release) to investors resident in the Province of Quebec. There is an amended and restated offering document related to this Offering dated August 19, 2026 that can be accessed under the Company's profile at www.sedarplus.ca and on the Compa
2026-08-19 1:06 PM EDT | Marvel Biosciences Corp.
Illumisoft Appoints Ehsan Agahi as CEO, Commences Trading on OTCQB Venture Market, Announces Shares for Debt Settlement
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) (OTCQB: FUVCF) ("Illumisoft" or the "Company") today announced that Ehsan Agahi, currently Executive Chairman of the Company, has been appointed Chief Executive Officer, effective August 19, 2026. Mr. Agahi will continue to serve as Chairman of the Board. As Executive Chairman since the completion of the Company's qualifying transaction, Mr. Agahi has been closely involved in Illumiso
Technology, Biotechnology, Healthcare and Hospitals, Household / Consumer / Cosmetics
2026-08-19 7:18 AM EDT | Illumisoft Lighting Corp.
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and regul
Biotechnology, Pharmaceuticals
2026-08-19 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Noveris Health Sciences Receives USPTO Notice of Allowance, and Signs Work Order with API
Vancouver, British Columbia--(Newsfile Corp. - August 18, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) ("Noveris" or the "Company") is pleased to announce that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for the Company's U.S. Patent Application No. 18/443,025, titled "Aza-Substituted Psilocin Analogs and Methods of Synthesizing the Same." The Notice of Allowance confirms that all
2026-08-18 5:05 PM EDT | Noveris Health Sciences Inc.
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or
Biotechnology, Pharmaceuticals
2026-08-18 8:00 AM EDT | PharmaTher Holdings Ltd.
PharmaCorp Closes Previously Announced Western Canada Pharmacy Acquisition and Announces Two Additional Definitive Agreements
Purchase price of approximately $2.47 million Acquisition increases PharmaCorp's operating network to 16 pharmacies New definitive share purchase agreement executed for a PharmaChoice Canada-bannered pharmacy in Western Canada at a purchase price of approximately $1.3 million New definitive asset purchase agreement executed for the prescription files of an I.D.A.-bannered pharmacy in Western Canada Saskatoon, Saskatchew
Biotechnology, Pharmaceuticals, Retail
2026-08-18 8:00 AM EDT | PharmaCorp RX Inc.
TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9
Technology, Biotechnology, Pharmaceuticals, Health
2026-08-18 7:00 AM EDT | TempraMed Technologies Ltd.
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closing FDA Type C Statistical Methods Meeting mid-September 2026 meeting to review 2.5-year Overall Survival data and confirmatory Phase 3 trial design to gain alignment on statistical analysis plan for BLA submission under the Accelerated Approval Program
2026-08-17 7:40 AM EDT | OS Therapies
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Ryan Simms, PhD, as Chief Operating Officer ("COO") and Head of Radiopharmaceutical Programs, strengthening the Company's leadership and deve
Biotechnology, Pharmaceuticals, Health
2026-08-17 3:15 AM EDT | Defence Therapeutics Inc.
Strategic Investment in Production Expansion: Impact Fusion International (IFUS) Installs Proprietary Machinery to Enhance Production Capacity
Napoleonville, Louisiana--(Newsfile Corp. - August 17, 2026) - IFUS (OTCID: IFUS) has installed a retrofitted Selco/Mosley Badger Double Ram Press. Per the Equipment Commissioning Plan, both SGP+™ and SAG™ will now be produced for validation to ensure consistent and sustainable product quality. Delivery and installation, supported by the Harris Bailer Distributor Crigler, has ensured that retrofitted production capability is consistent with IFUS' Proprietary Formulation and
2026-08-17 12:01 AM EDT | Impact Fusion International Inc.
Hanf.com Transaction Advances as Neural Therapeutics Receives CSE Conditional Approval
Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has received conditional approval from the Canadian Securities Exchange (the "CSE") for the listing of the Company's shares following completion of its previously announced fundamental change transaction involving CWE European Holdings Inc. ("CWE"), which operates the Hanf.com business in Germany (
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-08-14 5:01 PM EDT | Neural Therapeutics Inc.
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027
Halifax, Nova Scotia--(Newsfile Corp. - August 14, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2027, which ended on June 30, 2026. All figures are in Canadian dollars unless otherwise stated. "While ATI-1801 remains the Company's principal
Biotechnology, Pharmaceuticals, industries.supplementary-medicine.name
2026-08-14 5:00 PM EDT | Appili Therapeutics Inc.